Global Hydroxyprogesterone Caproate Injection Market is expected to grow at a CAGR of 5.2% from 2021 to 2030. The market is driven by the increasing number of women who are entering the workforce and are more likely to have children later in life, which increases their risk for preterm birth. The market is also driven by the increasing number of women who are opting for elective cesarean sections, which increases their risk for preterm birth. The 1mL injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 5mL one in 2025.Hospitals injection accounted for a larger market share of 51% in 2018, but it was expected to be exceeded by clinics injection in 2025.North America accounted for a larger market share of 39% in 2018 and it was expected to maintain its dominance throughout the forecast period due to high prevalence rates and increased awareness about preterm births among pregnant women as well as healthcare providers.
Some Of The Growth Factors Of This Market:
- The market for Hydroxyprogesterone Caproate Injection is growing at a significant rate due to the increase in the number of women who are entering their reproductive years.
- The market for Hydroxyprogesterone Caproate Injection is expected to grow at a significant rate due to the increase in awareness about its benefits and side effects among women.
- The market for Hydroxyprogesterone Caproate Injection is expected to grow at a significant rate due to the increasing number of women who are opting for natural birth control methods such as intrauterine devices and contraceptive pills, which have been shown not be effective enough in preventing pregnancy after discontinuation or failure of these methods respectively.
Industry Growth Insights published a new data on “Hydroxyprogesterone Caproate Injection Market”. The research report is titled “Hydroxyprogesterone Caproate Injection Market research by Types (1 mL Injection, 5 mL Injection, The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.), By Applications (Hospitals Injection, Clinics Injection, Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.), By Players/Companies AMAG Pharmaceuticals, Mcguff Pharmaceuticals Inc, Aspen Oss B.V, American Regent, Inc., Mylan Institutional”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Hydroxyprogesterone Caproate Injection Market Research Report
By Type
1 mL Injection, 5 mL Injection, The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
By Application
Hospitals Injection, Clinics Injection, Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
By Companies
AMAG Pharmaceuticals, Mcguff Pharmaceuticals Inc, Aspen Oss B.V, American Regent, Inc., Mylan Institutional
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Hydroxyprogesterone Caproate Injection Market Report Segments:
The global Hydroxyprogesterone Caproate Injection market is segmented on the basis of:
Types
1 mL Injection, 5 mL Injection, The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals Injection, Clinics Injection, Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AMAG Pharmaceuticals
- Mcguff Pharmaceuticals Inc
- Aspen Oss B.V
- American Regent, Inc.
- Mylan Institutional
Highlights of The Hydroxyprogesterone Caproate Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 1 mL Injection
- 5 mL Injection
- The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
- By Application:
- Hospitals Injection
- Clinics Injection
- Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hydroxyprogesterone Caproate Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hydroxyprogesterone caproate injection is a medication used to treat symptoms of menopause, such as hot flashes and vaginal dryness. It works by increasing the production of natural estrogen in the body.
Some of the major companies in the hydroxyprogesterone caproate injection market are AMAG Pharmaceuticals, Mcguff Pharmaceuticals Inc, Aspen Oss B.V, American Regent, Inc., Mylan Institutional.
The hydroxyprogesterone caproate injection market is expected to grow at a compound annual growth rate of 5.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hydroxyprogesterone Caproate Injection Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Hydroxyprogesterone Caproate Injection Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Hydroxyprogesterone Caproate Injection Market - Supply Chain
4.5. Global Hydroxyprogesterone Caproate Injection Market Forecast
4.5.1. Hydroxyprogesterone Caproate Injection Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Hydroxyprogesterone Caproate Injection Market Size (000 Units) and Y-o-Y Growth
4.5.3. Hydroxyprogesterone Caproate Injection Market Absolute $ Opportunity
5. Global Hydroxyprogesterone Caproate Injection Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Type
5.3.1. 1 mL Injection
5.3.2. 5 mL Injection
5.3.3. The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Hydroxyprogesterone Caproate Injection Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Application
6.3.1. Hospitals Injection
6.3.2. Clinics Injection
6.3.3. Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Hydroxyprogesterone Caproate Injection Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Hydroxyprogesterone Caproate Injection Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Hydroxyprogesterone Caproate Injection Demand Share Forecast, 2019-2026
9. North America Hydroxyprogesterone Caproate Injection Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Application
9.4.1. Hospitals Injection
9.4.2. Clinics Injection
9.4.3. Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Type
9.7.1. 1 mL Injection
9.7.2. 5 mL Injection
9.7.3. The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Hydroxyprogesterone Caproate Injection Demand Share Forecast, 2019-2026
10. Latin America Hydroxyprogesterone Caproate Injection Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Application
10.4.1. Hospitals Injection
10.4.2. Clinics Injection
10.4.3. Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Type
10.7.1. 1 mL Injection
10.7.2. 5 mL Injection
10.7.3. The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Hydroxyprogesterone Caproate Injection Demand Share Forecast, 2019-2026
11. Europe Hydroxyprogesterone Caproate Injection Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Application
11.4.1. Hospitals Injection
11.4.2. Clinics Injection
11.4.3. Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Euroe Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Type
11.7.1. 1 mL Injection
11.7.2. 5 mL Injection
11.7.3. The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Hydroxyprogesterone Caproate Injection Demand Share, 2019-2026
12. Asia Pacific Hydroxyprogesterone Caproate Injection Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Application
12.4.1. Hospitals Injection
12.4.2. Clinics Injection
12.4.3. Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Type
12.7.1. 1 mL Injection
12.7.2. 5 mL Injection
12.7.3. The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Hydroxyprogesterone Caproate Injection Demand Share, 2019-2026
13. Middle East & Africa Hydroxyprogesterone Caproate Injection Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Application
13.4.1. Hospitals Injection
13.4.2. Clinics Injection
13.4.3. Hospital took a larger market share of 51% in 2018, but it was expected to be exceeded by the Clinic in 2025.
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Hydroxyprogesterone Caproate Injection Market Size and Volume Forecast by Type
13.7.1. 1 mL Injection
13.7.2. 5 mL Injection
13.7.3. The 5 mL Injection accounted for a larger market share of 52% in 2018, but it was projected to be exceeded by the 1mL one in 2025.
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Hydroxyprogesterone Caproate Injection Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Hydroxyprogesterone Caproate Injection Market: Market Share Analysis
14.2. Hydroxyprogesterone Caproate Injection Distributors and Customers
14.3. Hydroxyprogesterone Caproate Injection Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AMAG Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Mcguff Pharmaceuticals Inc
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Aspen Oss B.V
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. American Regent, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Mylan Institutional
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
&n